Registration has opened for “PQA Convenes: Advancing Medication Therapy Management Quality Measurement,” which will take place on Thursday, November 2 in Arlington, Va. This invite-only event will bring together PQA members and industry experts to discuss the state of medication therapy management (MTM) practice, implications of recent Centers for Medicare & Medicaid Services (CMS) proposals and opportunities to evolve MTM quality measurement.
The Pharmacy Quality Alliance (PQA) seeks interested pharmacy and payer partners to participate in proof-of-concept pilots to implement and test high priority immunization pharmacy measure concepts.
PQA has launched the PQA Quality Innovation and Research Initiative to Advance Medication Therapy Management Quality Measurement – a national initiative to advance medication therapy management (MTM) quality measurement and other strategies to evaluate MTM services.
PQA has appointed 16 individuals from member organizations to serve on a technical expert panel (TEP) to review and provide input on draft specifications for the pharmacy measure concept, Specialty Pharmacy Prescription Abandonment Rate [Pharmacy] (SP-AR-PH).
PQA has appointed 19 individuals from member organizations to serve on a technical expert panel (TEP) to review and provide input on specific approaches to ensuring PQA’s measures support equitable health care.
Health outcomes can be influenced by many factors other than the health care services received, including patient-related factors such as existing clinical conditions and sociodemographic status (SDS), which refers to a variety of socioeconomic (e.g., income, education, occupation) and demographic factors (e.g., age, race, ethnicity, primary language).
PQA uses a systematic, transparent, and consensus-based process to conceptualize, specify, test, and endorse quality measures. Following endorsement by PQA’s membership, PQA measures can be implemented into various quality programs, including those maintained by the Centers for Medicare & Medicaid Services (CMS). Many PQA measures are used in CMS Quality Programs to evaluate safe and appropriate medication use among beneficiaries.
PQA has appointed individuals from member organizations to serve on the 2023 PQA Measure Update Panel (MUP) and Quality Metrics Expert Panel (QMEP).
PQA follows a systematic, transparent, and consensus-based process in the development and maintenance of measures. This process ensures that PQA measures are relevant and continue to support improvement in health care.
The Pharmacy Quality Alliance (PQA) has developed a new health plan performance measure focused on medication adherence, Proportion of Days Covered Composite (PDC-CMP). PQA is actively soliciting feedback on this measure via a public comment period which opened on October 3 and will close on October 24, 2022. Stakeholders are invited to provide comments.
PQA has appointed 15 individuals from member organizations to serve on a technical expert panel (TEP) to review and provide input on draft specification for a health plan performance measure concept: COPD (chronic obstructive pulmonary disease) Treatment Ratio (CTR).
PQA, the Pharmacy Quality Alliance, has begun developing a health plan performance measure for chronic obstructive pulmonary disease (COPD).
PQA follows a systematic, transparent and consensus-based development process to ensure that measures are important, scientifically acceptable, feasible and usable. However, the measurement lifecycle does not end when a measure is endorsed.
Quality measures are standards for measuring the performance of health care providers to care for patients and populations. PQA develops and stewards measures focused on medication use.
PQA follows a systematic, transparent and consensus-based development process to ensure that measures are important, scientifically acceptable, feasible and usable. This approach produces strong, consistent results, but it also takes time.
PQA has appointed 17 individuals from member organizations to serve on a technical expert panel (TEP) to review and provide input on draft specifications for a health plan measure concept: Proportion of Days Covered (PDC) Composite.
PQA follows a systematic, transparent and consensus-based development process to ensure that measures are important, scientifically acceptable, feasible and usable. This approach produces strong, consistent results, but it also takes time.
PQA has published the 2022 PQA Measure Manual and Value Sets. The PQA Measure Manual includes detailed narrative specifications for PQA measures, which are needed to implement the measures accurately and appropriately. PQA Value Sets, which include National Drug Codes (NDCs), are required to calculate PQA measures as specified.
The Pharmacy Quality Alliance (PQA) seeks interested pharmacy and payer partners to participate in proof-of-concept pilots to implement high priority blood pressure and hemoglobin A1c measure concepts in value-based payment arrangements (VBAs).
Prescription opioid-related deaths are one of the leading preventable public health problems. High-risk prescribing practices have contributed to the opioid overdose epidemic. These include overlapping opioid and benzodiazepine prescriptions, prescribing high-dose opioids and using multiple prescribers or pharmacies for opioid prescriptions.
